Home
Search
Placeholder Banner
Letters, Testimony and Comments

BIO Submits Comments on CDC Clinical Practice Guideline for Prescribing Opioids

April 11, 2022

On Monday, April 11th, BIO also submitted comments in response to the CDC’s recently published Clinical Practice Guideline for Prescribing Opioids. In the comments submitted, BIO primarily requested that the CDC revise its language referencing naloxone to be consistent with more general and product agnostic references, e.g., FDA-approved opioid overdose reversal medication.

Download Full Comments Below
BIO COMMENT LETTER CDC Guideline for Prescribing Opioids
Download
Discover More
BIO Comments on FDA Guidance: Clinical…
On Monday, May 9th, BIO submitted comments in response to the FDA’s recent draft guidance on Clinical Pharmacology Considerations for Antibody-Drug Conjugates. In the comments submitted, BIO acknowledged the challenge FDA faces in creating a…
Learn more
BIO Comments on Upcoming ODAC Pediatric Oncology…
On Wednesday, April 27th, BIO submitted comments regarding an upcoming meeting of ODAC’s Pediatric Oncology Subcommittee on PREA Waivers for Same-in-Class Drugs. In particular, the subcommittee will meet to discuss the development of a conceptual…
Learn more
BIO Submits Comments on FDA Draft Guidance for…
On Monday, April 11th, BIO submitted comments in response to the FDA’s recent draft guidance on the Development of Non-Opioid Analgesics for Acute Pain. In the comments submitted, BIO reaffirmed its commitment to working with the Agency to achieve…
Learn more